It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug ...

Analysts, who are highly bullish on the stock, have fretted for some time that Viking needed a partner to actually make the ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Viking Therapeutics ( VKTX -0.30%) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...

And Viking said it has worked with Corden in the past, although it declined to specify on which drug. Under the terms of the deal, Viking will make prepayments to Corden of $150 million over the ...

It also looks like this big pharma giant will own the top obesity drug for the foreseeable future. If Viking Therapeutics starts a phase 3 trial for VK2735 tomorrow, it will still be more than a ...

Viking Therapeutics Inc.’s stock soared 8% ... to support the commercialization of its oral obesity drug VK2735. The deal covers supply of both the active pharmaceutical ingredient, or API ...